Shuai Li

Shuai Li, MD/PhD, is a Medical Director at Genentech since January 2022, with previous roles as a Thoracic Oncologist at Shanghai Pulmonary Hospital and a Research Fellow at Dana-Farber Cancer Institute. Extensive experience includes leading projects on lung cancer, particularly focusing on treatments targeting KRAS and EGFR mutations, as well as studying the tumor microenvironment. Academic contributions comprise multiple publications in prestigious journals and presentations at international conferences, with notable works detailing the impact of genetic alterations on treatment resistance and efficacy in non-small cell lung cancer (NSCLC). Education includes a Medical Doctorate and a dual PhD in Oncology from Tongji University, completed in 2018.